Background and Objectives: Severe, recalcitrant cases of pediatric psoriasis or 
atopic dermatitis may necessitate treatment with biological agents; however, 
this may be difficult due to lack of treatment options and standardized 
treatment guidelines. This review evaluates the biological treatment options 
available, including off-label uses, and provides a basic therapeutic guideline 
for pediatric psoriasis and atopic dermatitis. Materials and Methods: A PubMed 
review of biological treatments for pediatric psoriasis and atopic dermatitis 
with information regarding age, efficacy, dosing, contra-indications, adverse 
events, and off-label treatments. Results: Currently there are three European 
Medicines Agency (EMA)-approved biological treatment options for pediatric 
psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently 
Food and Drug Administration (FDA)- and EMA-approved for adult atopic 
dermatitis, it is still not yet approved for pediatric atopic dermatitis. 
Conclusions: Given the high morbidity associated with pediatric atopic 
dermatitis and psoriasis, there is a need for more treatment options. Further 
research and post-marketing registries are needed to extend the use of biologics 
into pediatric patients.